3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Colorectal Neoplasms
1
Carcinoma, Basal Cell
1
Breast Carcinoma In Situ
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
Cisplatin
7
Oxaliplatin
5
Paclitaxel
4
Fluorouracil
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
Taxes
3
Mitomycin
3
130-nm albumin-bound paclitaxel
3
Nivolumab
2
Leucovorin
2
Doxorubicin
2
veliparib
1
tremelimumab
1
talimogene laherparepvec
1
soluble LAG-3 protein, human
1
sodium thiosulfate
1
pembrolizumab
1
nintedanib
1
irinotecan sucrosofate
1
durvalumab
1
dehydroftorafur
1
cc-486
1
avelumab
1
Trastuzumab
1
Semaxinib
1
Radiotherapy
1
Radiation
1
Platinum
1
Pharmacogenomic Variants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Peritoneal Neoplasms
×
talimogene laherparepvec
×
Clear all
NCT03663712
2024-11-20
TEMPO
Duke University
Phase 1
Completed
28 enrolled
10 charts